At Dabur, we understand that innovation is critical to our sustained success. We have completely overhauled our innovation process, making it more flexible, fast, and highly consumer focused. This transformation helped us deliver solutions in record time to meet our consumers' needs during the COVID pandemic.
Over our 137 years of existence, Dabur has built a repertoire of intangible and knowledge-based assets. Our deep-rooted understanding of Ayurveda; our brands, which evoke feelings of trust in the minds of our consumers; our patents and copyrights; our unwavering focus on quality; and our employees' knowledge of protocols and procedures form our Intellectual Capital that supports our commitment to deliver Health & Well-Being to every household.
We draw on our immense pool of expertise and experience to constantly innovate and develop products that meet the ever-changing and evolving needs of our consumers across the globe.
At Dabur, we understand that innovation is critical to our sustained success. We have completely overhauled our innovation process, making it more flexible, fast, and highly consumer focused. This transformation helped us deliver solutions in record time to meet our consumers’ needs during the COVID pandemic.
At Dabur, we encourage our employees to promote innovation. We rely on traditional research and development as much as on the great potential for creativity throughout the Company to drive innovation at Dabur. We increased our R&D spends during the year as our business and operations teams worked throughout the lockdown to create a range of products to cater to the growing consumer need for health and hygiene. A majority of these new rollouts happened within two months of the COVID outbreak with a number of products, which were already in various stages of development, being fast-tracked for launch. In addition to expanding our already strong portfolio of immunity boosting Ayurvedic health care offerings, we also made a tactical foray into the personal and household hygiene space with a range of sanitisers, soaps, household cleaning products and disinfectants. Our flexibility, agility, and capacity to make rapid choices and implement them contributed well to our business during the COVID year.
The innovation drive continues at Dabur we are adding more products to our portfolio to offer ageold Ayurvedic remedies in convenient and modern formats. In addition to strengthening our portfolio, the new introductions will help us build a better connect with millennials and centennials.
In order to maintain and reinforce our position in the global arena, we are also continuously driving innovation to optimise our manufacturing and processing procedures, application areas, and Go-to-Market strategies. We have implemented Continuous Replenishment System (CRS) to manage our inventories better, which has helped us reduce the pipeline inventory by 5-7 days. Communication and connecting with partners and business associates have become more seamless today, enabled by technology. Technology has, in fact, gained substantial prominence in the organisation now. We also recognize employee projects from around the world to celebrate innovative ideas for products and applications, production and production processes, business models and commercialization, internal business processes, and patents and intellectual property.
Dabur is amongst the oldest Ayurvedic and natural consumer products maker in the world. We had established an R&D Centre way back in 1919 to develop scientific processes and quality checks for mass production of traditional Ayurvedic medicines. The first Clinical study was conducted by Dabur more than 25 years ago with our flagship brands Dabur Chyawanaprash and Dabur Amla hair oil being some of the earliest products to be tested clinically in early 1990s.
To generate the evidence, Dabur conducts scientific studies (both Pre-Clinical & Clinical) on existing products as well as on new products. We conduct scientific studies through a third party CRO (Contract Research Organization) following all applicable guidelines like OECD guidelines for Pre-Clinical studies and ASU GCP & ICH GCP guidelines for Clinical Studies. Clinical Studies are registered at CTRI (Clinical Trial Registry of India – ICMR portal) and are conducted after taking approvals from concerned Ethics committee and Written Informed Consent process from study participants before initiating the study.
At Dabur Research & Development Centre (DRDC), we have put in place more than 35 SOPs (Standard Operating Procedures) to conduct such studies. The duration of the studies depends on the model selected for the Scientific Study. Pre-Clinical studies may be completed within few weeks to a few months, whereas Clinical studies usually take longer, which may vary from a few months to more than one year depending on the number of subjects, number of groups and many other variables involved in the study.
Clinical Study suggests regular intake of Dabur Chyawanprash reduces risk of COVID-19 infection
In a major breakthrough development during the year, Dabur completed a large scale, multi-centric, clinical study to validate the beneficial role of Dabur Chyawanprash in prophylaxis of COVID-19 infection by virtue of its immunity boosting property. This study was conducted at five different scientific/research institutions across India (one each at Jaipur, Mumbai and Pune and two in Vadodara). In fact, this study has already been submitted for publication in a scientific journal, which will also be peer reviewed. The findings of the study reveal that regular use of Dabur Chyawanprash reduced the risk of COVID-19 infection by up to 12 times in comparison to control group which was not consuming Chyawanprash. It was also noted that with regular usage of Dabur Chyawanprash, there was up to 6 times lesser severity of COVID 19 infections when compared to subjects in control group.
The study was conducted by a team of modern medical doctors, as per protocol, after getting ethics committee (IEC) approvals for all the study sites and registering with Clinical Trials Registry of India (CTRI), an Indian Council of Medical Research (ICMR) portal. The study followed applicable GCP guidelines and was conducted after taking informed consent from all the study subjects. In the Clinical study, WHO Ordinal Scale was used to know the severity of infection among the subjects who were tested positive. A total of 721 subjects were enrolled in this clinical study. Of these, 696 subjects completed the study, out of which 351 subjects were in Dabur Chyawanprash group (took 1 tsp Chyawanprash twice daily for 90 days) and 345 subjects were in control group which was not taking Chyawanprash.
In tested subjects who consumed Dabur Chyawanprash, a lesser incidence of COVID-19 infections was observed. Also, the severity of infection was mild in Dabur Chyawanprash group whereas the severity went up to severe level in the control group. In this study, subjects using Dabur Chyawanprash also had lesser incidence of influenza-like symptoms in comparison to the non-Chyawanprash users. As compared to subjects in the non-Dabur Chyawanprash group, the overall quality of life Index found to be significantly better in subjects using Chyawanprash as assessed using a validated questionnaire.
Dabur is conducting studies for Prophylaxis and management of COVID-19, along with various State Governments and the Ministry of AYUSH. This offers a great opportunity for Dabur to make Ayurveda mainstream and popularise hitherto hidden gems of Ayurveda for prophylactic healthcare. The National Clinical Management Protocol based on Ayurveda and Yoga for management of COVID-19 also mentions Chyawanprash in prophylactic care of COVID-19. Besides, the apex research body of Ayurveda CCRAS (The Central Council for Research in Ayurvedic Sciences) had also conducted a clinical study on Chyawanprash for the prevention of COVID-19 infection among healthcare workers where Dabur Chyawanprash was used.
India's Healthcare ecosystem is on the cusp of a paradigm shift with digital technology-driven medical assistance becoming a necessity in the post-COVID world. The pandemic and the subsequent lockdown have led to a marked change in consumer behaviour as traditional ways of in-person doctor-patient interaction are limited. This has resulted in widespread adoption of telemedicine in the country.
As part of our attempts to make Ayurveda mainstream and bring it closer to consumer households, we have rolled out Dabur Arogya which aims to provide Ayurvedic treatment to various ailments through telemedicine – capitalizing our Ayurvedic knowhow, panel of Ayurveda doctors and facility of online consultation.
Dabur Arogya has been established as teleconsultation and telemedicine channel that allows consumers and patients to connect with our empanelled Ayurvedic practitioners and seek free consultation for any health concern over the phone or on WhatsApp. We have a panel of over 26,000 experience Ayurvedic practitioners connected with us on this platform. Dabur Arogya has helped us break geographic boundaries for improving patient access to care.
We regard intellectual property as one of our vital management resources, and understand that good Intellectual Property management can help translate the results of our creativity and innovation into profits and valuable businesses.
Over the years, Dabur has built a solid position in Ayurvedic Health Care and secured several Product Process patents, including bio-medical patents for Ayurvedic formulations. These have further established Dabur's Ayurvedic credentials and leadership in the marketplace. Dabur has been working on constructing a high-quality patent portfolio. As of March 31, 2021, we have 11 issued patents and 45 publicly filed patent applications in India. Dabur’s global IPR portfolio comprises of 2,827 registered trademarks and 811 pending trademark applications.
We believe the protection of our trademarks, copyrights, domain names, trade names, trade secrets, patents and other proprietary rights is critical to our business. We rely on a combination of trademark, fair trade practice, copyright and trade secret protection laws and patent protection in India and other geographies to protect our intellectual property and our trademarks.
- 2 Patent applications filed in 2020-21
- 45 Patent applications filed by Dabur till date
- 11 Patents granted till date
- 5 Research Observations published & 2 accepted for publishing in Peer Review Journals in 2020-21
Dabur is committed to pursuing induction of new technology and use of digital tools in research and development. We have used data analysis for a number of years now for our R&D processes, and continually invest in employees and infrastructure to build our R&D capability.
At our Analytical division in Dabur Research & Development Centre (DRDC), we develop powerful analytical methods to ensure that our products are free of contaminants, optimise our process to ensure our products meet the highest quality and safety standards, support product innovation with scientific approaches, advanced analytical tools and the latest detection technologies.
While established, officially approved methods are used to monitor for known issues, we also develop new analytical methods to respond to unforeseen issues as they emerge. Some of the advanced analytical techniques that are increasingly being imbibed in developing robust quality ecosystem are Liquid Chromatography/Elemental Analysis-Isotope Ratio Mass Spectrometry (LC/EA-IRMS), Liquid Chromatography with Tandem Mass Spectrometry (LC-MS-MS), Gas Chromatography - Tandem Mass Spectrometry (GC-MS-MS), Inductively Coupled Plasma Mass Spectrometry (ICP-MS), High-Performance Thin-Layer Chromatography Mass Spectrometry (HPTLC-MS), Liquid Chromatography–Mass Spectrometry (LC–MS), Ultra-Performance Liquid Chromatography (UPLC), etc.
In Product Performance Evaluation (PPE) function, we work on product formulation optimisation, formulation cost optimisation, evaluating performance of formulations as perceived by the end-consumer, evaluating product claims robustness before outsourcing for 3P claims studies, new method development for claims testing and delivering soft product claims and scientific demos for marketing communications. The team has expertise in handling sensory evaluations in line with international guidelines and instrumental evaluation of key skin and hair parameters.
DRDC-Analytical plays a pivotal part in the successful deliverance of all our product improvement, cost reduction, product development and import substitution projects.
Dabur is today the first Indian company to import the Nuclear Magnetic Resonance (NMR) spectroscopy machine. It is an analytical technique used to determine the molecular structure of samples, which are then compared to spectral libraries (database) of the same item. This database is developed over years by analysing large and diverse sets of samples of the same item. While it is widely used in wine in European countries, NMR spectroscopy is just starting to be experimented to evaluate honey. NMR allows rapid, but database-driven detection and quantification of various chemical compounds, especially for authenticating the origin of a sample of honey. Prior existence of a database is an absolute necessity for effective utilisation of this technique. Since no such database exists at present for Indian honey, NMR testing will have limited utility in the Indian context. Understanding this gap, we are alongside working towards creating a comprehensive and representative database for Indian Honey that fully reflects the natural variability of honey composition from all producing regions of the country, including the effects of seasonal variation, effect of multiple floras present in the country and blending.
- 218 New method development/method optimization undertaken across categories
- 123 Preservative Efficacy Testing undertaken to ensure robustness of products
- 172 Anti-microbial efficacy testing undertaken
- 600 Claims studies undertaken
To remain innovative, Dabur works closely with its consumers around the world, besides collaborating with partners from academia. We maintain longstanding and strategic partnerships with variousacross the globe. In Product Performance Evaluation, for instance, Dabur has initiated studies renowned international research institutes like TRI, Princeton, USA; and is working on two research publications.